Zobrazeno 1 - 10
of 57
pro vyhledávání: '"Antonia, Ridolfi"'
Autor:
Mirko Fillbrunn, James Signorovitch, Fabrice André, Iris Wang, Ines Lorenzo, Antonia Ridolfi, Jinhee Park, Akanksha Dua, Hope S. Rugo
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-11 (2022)
Abstract Background Approximately 40% of hormone receptor positive/human epidermal receptor 2 negative (HR + /HER2-) metastatic breast cancer (mBC) patients harbor phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) mutati
Externí odkaz:
https://doaj.org/article/7754d2c3a2fb47a9bd75569fd3c08e6a
Autor:
María Luz Ruiz-Falcó Rojas, Martha Feucht, Alfons Macaya, Bernd Wilken, Andreas Hahn, Ricardo Maamari, Yulia Hirschberg, Antonia Ridolfi, John Chris Kingswood
Publikováno v:
Frontiers in Pharmacology, Vol 13 (2022)
The TuberOus SClerosis registry to increase disease Awareness (TOSCA) Post-Authorization Safety Study (PASS) was a non-interventional, multicenter, safety substudy that assessed the long-term safety of everolimus in patients with tuberous sclerosis c
Externí odkaz:
https://doaj.org/article/d7a5927dfb6849c78b7004917ea2fba5
Autor:
Peter A. Fasching, J. Thaddeus Beck, Arlene Chan, Michele De Laurentiis, Francisco J. Esteva, Guy Jerusalem, Patrick Neven, Xavier Pivot, Giulia V. Bianchi, Miguel Martin, David Chandiwana, Brad Lanoue, Antonia Ridolfi, Yingbo Wang, Karen Rodriguez Lorenc, Arnd Nusch
Publikováno v:
Breast, Vol 54, Iss , Pp 148-154 (2020)
Purpose: In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and
Externí odkaz:
https://doaj.org/article/a5b481e9a0e5458182d897e58fbb782f
Publikováno v:
Journal of Biopharmaceutical Statistics. :1-8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6d03ef71dd62302520cfa4587e27b6a9
https://doi.org/10.1080/10543406.2023.2170406
https://doi.org/10.1080/10543406.2023.2170406
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-4 (2018)
Abstract Background RECORD-4 assessed everolimus in patients with metastatic renal cell carcinoma (mRCC) who progressed after 1 prior anti-vascular endothelial growth factor (VEGF) or cytokine and reinforced the clinical benefit of second-line everol
Externí odkaz:
https://doaj.org/article/dcbf67ee409b4411a43e83222f00ae51
Autor:
Masakazu Toi, Zhimin Shao, Sara Hurvitz, Ling-Ming Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Jifeng Feng, Binghe Xu, Xiaojia Wang, Keun Seok Lee, Ting Ying Ng, Antonia Ridolfi, Florence Noel-baron, Francois Ringeisen, Zefei Jiang
Publikováno v:
Breast Cancer Research, Vol 19, Iss 1, Pp 1-13 (2017)
Abstract Background The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in
Externí odkaz:
https://doaj.org/article/3f86af985baa4e6283f302dee1bbb3e7
Autor:
Hiroji Iwata, Antonia Ridolfi, Christelle Levy, Yeon Hee Park, Ines Lorenzo, Fabrice Andre, Dejan Juric, Mario Campone, Tamar Safra, Hope S. Rugo, Norikazu Masuda, Frederic Forget, Juan Ignacio Delgado Mingorance, Ingrid A. Mayer, Sibylle Loibl, Pierfranco Conte, Jinhee Park, Eva Ciruelos, Xiaolei Zhou
Publikováno v:
Journal of Clinical Oncology. 39:2005-2015
PURPOSE In the phase III SOLAR-1 trial ( NCT02437318 ), the PI3Kα-selective inhibitor and degrader alpelisib significantly improved median progression-free survival when added to fulvestrant in patients with phosphatidylinositol-4,5-bisphosphate 3-k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::900306b89133fc27c05b81e52eaff70b
https://doi.org/10.1200/jco.20.01139
https://doi.org/10.1200/jco.20.01139
Autor:
Hope S. Rugo, Stephen Chia, Wei-Chun Hsu, Juan Pablo Zarate, Hemanth Kanakamedala, David Chandiwana, Chu-Ling Yu, Jinhee Park, Antonia Ridolfi, Stuart J. Turner
Publikováno v:
The Oncologist
Background The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (AB
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e2cb8cbf42e6cfbe7074f0e9f4f106b9
http://europepmc.org/articles/PMC8265362
http://europepmc.org/articles/PMC8265362
Autor:
Patrick Neven, Xavier Pivot, Antonia Ridolfi, Brad Lanoue, J. Thaddeus Beck, Guy Jerusalem, Arnd Nusch, Francisco J. Esteva, Giulia Bianchi, David Chandiwana, Miguel Martin, Karen Rodriguez Lorenc, Peter A. Fasching, Arlene Chan, Yingbo Wang, Michele De Laurentiis
Publikováno v:
The Breast : Official Journal of the European Society of Mastology
Breast, Vol 54, Iss, Pp 148-154 (2020)
Breast, Vol 54, Iss, Pp 148-154 (2020)
Purpose In the MONALEESA-3 Phase III trial of patients with hormone receptor–positive human epidermal growth factor receptor–negative advanced breast cancer, ribociclib plus fulvestrant significantly improved progression-free survival (PFS) and o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50428c3c87ca0b4950c30fbc684a2606
https://doi.org/10.1016/j.breast.2020.09.008
https://doi.org/10.1016/j.breast.2020.09.008
Autor:
Fabio Franke, Nadia Harbeck, Antonia Ridolfi, Brad Lanoue, Paul Wheatley-Price, Sara A. Hurvitz, David Chandiwana, Lakshmi Menon, K. Gonvind Babu, Aditya Bardia, Young-Hyuck Im, Debu Tripathy, Kadri Altundag
Publikováno v:
Cancer Research. 80:P1-19
Background: MONALEESA-7 is a Phase III study (NCT02278120) and the only dedicated trial of endocrine therapy (ET) ± a cyclin-dependent kinase 4/6 inhibitor in premenopausal patients with hormone receptor-positive, human epidermal growth factor recep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e0be9afe6fd21032421cf9157f6690c
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-06
https://doi.org/10.1158/1538-7445.sabcs19-p1-19-06